Blueprint Medicines to report first quarter 2018 financial results on Wednesday, May 2, 2018
Autolus announces license agreement with UCL Business PLC for clinical-stage product candidate in development for the treatment of B-cell malignancies
Autolus announces presentation of preliminary data showing early signs of clinical activity for a GD2-targeting CAR T cell therapy in a solid tumour setting at the AACR Annual Meeting
Blueprint Medicines publication in Cancer Discovery highlights preclinical and clinical proof-of-concept data for highly selective RET inhibitor BLU-667
Blueprint Medicines announces proof-of-concept data for highly selective RET inhibitor BLU-667 from Phase 1 ARROW clinical trial in patients with RET-altered solid tumors
Jounce Therapeutics to present nonclinical translational data at the 2018 AACR Annual Meeting
Kura Oncology announces upcoming presentations at AACR Annual Meeting 2018
TRACON Pharmaceuticals announces closing of previously announced private placement and appointment of Ted Wang, Ph.D., of Puissance Capital Management, to Board of Directors
Autolus and Miltenyi Biotec sign strategic supply agreement
Arvinas completes USD 55 million Series C financing to advance protein degradation platform
TRACON Pharmaceuticals announces USD 38.7 million private placement
Peloton Therapeutics appoints Helen S. Kim, M.B.A. and David Chang, M.D., Ph.D. to Board of Directors
Autolus announces oral presentation at the AACR Annual Meeting of a Phase I study of a GD2 CAR-T cell Therapy in patients with neuroblastoma
Autolus announces publication in Molecular Therapy on its small molecule-activated fast-acting permanent off switch
Autolus to support UK network of Advanced Therapies Treatment Centres
IDEAYA Biosciences raises USD94 million crossover Series B financing
Blueprint Medicines to present proof-of-concept data from ongoing Phase 1 clinical trial of BLU-667 in patients with RET-altered solid tumors in a clinical trials plenary session at AACR Annual Meeting 2018
Autolus appoints former Chief Operating Officer of Kite Pharma, Cynthia M. Butitta, to Board of Directors
Kura Oncology provides regulatory update on tipifarnib and reports fourth quarter and full year 2017 financial results
Jounce Therapeutics reports fourth quarter and full year 2017 financial results
19TH ANNUAL BIO€QUITY EUROPEGhent, Belgium
11th Annual European Life Sciences CEO Forum & ExhibitionZurich, Switzerland
J.P. Morgan 36th Annual Healthcare ConferenceSan Francisco, USA
59th ASH Annual MeetingAtlanta, USA
BioFIT 2017Strasbourg, France
Family Office ForumZürich
Keep me updated about investment opportunities in the area of oncology and life sciences.
April 2018October 2017May 2017February 2017
Please fill in the subscription form completely. If you wish to modify your personal data or to change/cancel your newsletter subscription, this is possible at any time. A link to your subscription profile can be found in every newsletter email.
Newsletters * Nextech Invest News Preview
Salutation * Ms./Mrs. Mr. Company
Company
First name *
Surname *
Address
ZIP / City
Email *
* Compulsory fields
Your eMail have been successfully registered.
